Specifically, the prevalence of anti-MDA5 autoantibodies in JIIM is up to 40% in Japan, while <10% in Western countries and in India.[5,8–13] ILD was regarded as a distinguished feature in anti-MDA5-positive JIIM patients in North America and Japan,[9,10,14] while this finding is not confirmed in cohorts of UK and India.[8,11] Besides, the expression of myxovirus-resistance protein A (MxA) also remains undetermined. This evidence concerns the gene MX1 and interstitial lung disease.